Alvotech, of Reykjavik, Iceland, reported Jan. 29 that it had reached a settlement and license agreement with Regeneron and Bayer that resolves all remaining patent disputes worldwide for its biosimilar to Eylea (aflibercept).

The settlement allows Alvotech and its commercial partners to market the biosimilar as of Jan. 1, 2026, in the UK and Canada; from May 1, 2026, in Europe, other countries (excluding the US), and Japan (though excluding the indication of diabetic macular edema, or DME, in Japan); and from Nov. 1, 2026, in Japan for all approved indications. The remaining terms of the agreement remain confidential.

Alvotech had previously announced a deal with Regeneron to bring the biosimilar to market in the US no later than the second half of 2026, pending FDA approval. Teva Pharmaceutical holds the US rights.

AVT06 was approved in August 2025 in Europe and the UK, where it is known as Mynzepli and Afiveg. It is indicated for wet age-related macular degeneration (AMD), macular edema secondary to retinal vein occlusion, DME, and myopic choroidal neovascularization.

UK-based Advanz Pharma holds the rights for most countries in Europe.

AVT06 was approved as Aflibercept BS in Japan, where Fuji Pharma holds the rights.

Alvotech announced Feb. 2 that it had reached a deal with Swiss drugmaker Sandoz for rights in Canada to “one biosimilar candidate in ophthalmology supplied as a prefilled syringe for intravitreal injection,” without naming the candidate. No further details were disclosed.

More News

Want to Read Locked Articles?

Already Have an Account?

Register A Corporate Account

Topics of Interest

Products of Interest